Duchenne Group's Presentation Is Milestone For Patient Involvement

Advocacy group gets portion of Sarepta's formal presentation period to present eteplirsen patient experience data, believed to be a first for an advisory committee meeting. Will it become commonplace?

FDA may have reached a new milestone in its effort to incorporate patient views into the drug review process when a Duchenne muscular dystrophy patient group obtained a prominent position in the eteplirsen advisory committee meeting presentations.

During the April 25 Peripheral and Central Nervous System Drugs Advisory Committee meeting, the Jett Foundation, a Duchenne advocacy group,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America